Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled inactivated Mycobacterium phlei for moderate bronchial asthma
ChiCTR-TRC-11001189Phase 3Completed
- Sponsor
- Health Commission of Guangxi Zhuang Autonomous Region
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of inactivated mycobacterium phlei and salmeterol + fluticasone in asthma (2 arms), sponsored by Health Commission of Guangxi Zhuang Autonomous Region. Primary endpoints: Amount and proportion of gamma-delta T-cell subsets, Number of gamma-delta T cells and subsets and 5 more. Started Jan 2012; status: completed.
02
Drugs
inactivated mycobacterium phleisalmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR-TRC-11001189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001189.